Cereno Scientific to present new preclinical data for drug candidate CS585 at scientific conference Vascular Discovery 2023: From Genes to Medicine
Cereno Scientific (XSAT: CRNO B) today announced that an abstract on the preclinical drug candidate CS585 has been accepted as an oral presentation at the scientific conference Vascular Discovery 2023: From Genes to Medicine hosted by the American Heart Association, in Boston, Massachusetts, US, May 10-13, 2023. The abstract titled “The eicosanoid analogue CS585 represents a first-in-class in prevention of platelet activation and thrombosis through direct activation of the prostacyclin receptor” will be presented by Adriana Yamaguchi, Postdoctoral Research Fellow at the University of Michigan.